Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 135Breast 18Genitourinary 14Thoracic 9Plasma cell 8Other hematologic neoplasm 8Myeloid 8Lymphoid 8Dermatologic 8CNS 8Sarcoma 6Gastrointestinal 6Endocrine 2Other solid neoplasm 1Other 1NET 1Head & Neck 1Classical hematology 1

Conditions

Neuroendocrine Tumors 102Carcinoid Tumor 22Neoplasms 16Neoplasm Metastasis 10Gastro-enteropancreatic neuroendocrine tumor 10Carcinoma, Neuroendocrine 9Adenoma, Islet Cell 9Pancreatic Neoplasms 7Carcinoma 7Pheochromocytoma 6Paraganglioma 6Neuroblastoma 6Colorectal Neoplasms 6Carcinoma, Islet Cell 6Somatostatinoma 5Gastrointestinal Neoplasms 5Vipoma 4Small Cell Lung Carcinoma 4Serotonin Syndrome 4Neuroectodermal Tumors, Primitive 4Melanoma 4Medulloblastoma 4Lung Neoplasms 4Intestinal Neoplasms 4Gastrinoma 4Carcinoma, Non-Small-Cell Lung 4Adenocarcinoma 4Prostatic Neoplasms 3Neuroectodermal Tumors 3Neoplasms, Nerve Tissue 3

Interventions

taxane 1liposomal doxorubicin 1Vinorelbine 1RRx-001 1Pemetrexed 1Paclitaxel 1Irinotecan 1Gemcitabine 1Etoposide 1Cisplatin 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Ovarian Epithelial × NET × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡